Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Terns Completes $87 Million Financing to Advance Three NASH Candidates

publication date: Jan 5, 2021

Terns Pharma, a San Mateo-Shanghai biopharma, completed a $87 million Series C round to support its three lead NASH programs. The financing was led by Deerfield Management Company and included a strategic equity investment from Eli Lilly. In 2018, Terns was founded with three small molecule targeted therapies for NASH that it in-licensed from Lilly and also an initial $30 million Lilly investment. Terns has development teams in California and Shanghai, though it plans to commercialize its products mainly in China. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021